1. Home
  2. MBRX

MBRX

Moleculin Biotech Inc.

Logo Moleculin Biotech Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-12-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of highly resistant tumors and viruses. The company's lead program, Annamycin is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.

Founded: 2015 Country:
United States
United States
Employees: N/A City: HOUSTON
Market Cap: 10.3M IPO Year: 2016
Target Price: $35.00 AVG Volume (30 days): 153.5K
Analyst Decision: Strong Buy Number of Analysts: 3
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -15.07 EPS Growth: N/A
52 Week Low/High: $0.34 - $6.24 Next Earning Date: 05-09-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: